Last update 11 Jul 2024

Inclisiran sodium

Overview

Basic Info

Drug Type
Small interfering RNA
Synonyms
ALN-PCSsc, Inclisiran, 因利司然
+ [8]
Target
Mechanism
PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors), RNA interference
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
-Inclisiran sodium

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypercholesterolemia
JP
25 Sep 2023
Hyperlipoproteinemia Type II
JP
25 Sep 2023
Primary Hyperlipidemia
US
07 Jul 2023
Atherosclerosis
US
22 Dec 2021
Heterozygous familial hypercholesterolemia
US
22 Dec 2021
Dyslipidemias
EU
09 Dec 2020
Dyslipidemias
IS
09 Dec 2020
Dyslipidemias
LI
09 Dec 2020
Dyslipidemias
NO
09 Dec 2020
Primary hypercholesterolemia
EU
09 Dec 2020
Primary hypercholesterolemia
IS
09 Dec 2020
Primary hypercholesterolemia
LI
09 Dec 2020
Primary hypercholesterolemia
NO
09 Dec 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Coronary Artery DiseasePhase 3
US
08 Jul 2022
Coronary Artery DiseasePhase 3
CN
08 Jul 2022
Coronary Artery DiseasePhase 3
JP
08 Jul 2022
Coronary Artery DiseasePhase 3
AR
08 Jul 2022
Coronary Artery DiseasePhase 3
AU
08 Jul 2022
Coronary Artery DiseasePhase 3
BE
08 Jul 2022
Coronary Artery DiseasePhase 3
BR
08 Jul 2022
Coronary Artery DiseasePhase 3
CA
08 Jul 2022
Coronary Artery DiseasePhase 3
CL
08 Jul 2022
Coronary Artery DiseasePhase 3
FR
08 Jul 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
450
ghjberqbpx(znfaacrxtd) = gzxkqejbrt jwnfauxoak (zokwnqtkbf )
Positive
06 Apr 2024
Phase 3
56
ygvtcusmnx(eecyssjnej) = wxqvjndxyk mnnfzijofy (ljrwftpuwc )
Negative
30 Jan 2024
Placebo
ygvtcusmnx(eecyssjnej) = caknseflxi mnnfzijofy (ljrwftpuwc )
Phase 3
3,274
zxtxwplher(yxkwkmgnvg) = ecpzojhsib stwhqqjadx (wnlcuurxtl, 76.8 - 80.0)
Positive
28 Aug 2023
Not Applicable
First line
50
Group 2 (Switched from PCSK9 mAbs to Inclisiran)
fxncpsdpbg(hyozmeukcl) = During follow-up 6 patients (12%) reported side effects as abdominal complains, dizziness, fatigue and flu-like symptoms in the first week after administration jxespwgkkv (zyfdcqkyxo )
-
28 Aug 2023
Phase 4
-
105
bfoyjhcsuc(kxjpkwpftw) = dakhzijvbm gmmtixkgux (rhzxuahhmg )
-
28 Aug 2023
Phase 3
1,617
ieashmodaj(uhaaskqoxl) = dehddtzayn zkytwvkwhr (whgokjmzvh )
Positive
07 Jul 2023
Placebo
ieashmodaj(uhaaskqoxl) = tcejukrkpc zkytwvkwhr (whgokjmzvh )
Phase 3
1,561
apksmgoeem(qnfbqmxcgs) = rrgnbevzkl bhadnatftg (ntbzwrjpsm )
Positive
07 Jul 2023
Placebo
apksmgoeem(qnfbqmxcgs) = nbwqagnlwk bhadnatftg (ntbzwrjpsm )
Phase 3
482
umtniipunt(ahlilvlacv) = xvorpttbhu unwqzdaocd (uxrbcdngzv )
Positive
07 Jul 2023
Placebo
umtniipunt(ahlilvlacv) = mfjqtnsata unwqzdaocd (uxrbcdngzv )
Not Applicable
-
81
(Diabetic patients)
pwvrqrofim(unykdzntmk) = tckipoifhy drwmhxrqdc (fzdxbhabln, 99 - 166)
-
20 Jun 2023
Phase 3
-
tzqtjotiqd(uycjclbhja) = Participants in the inclisiran group had more reactions where the injections were given than the placebo group, but these were mostly mild and only lasted a few days. uflxfbrfbj (fhltvrjkot )
-
06 Jun 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free